Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods.
GPC3 (glypican 3) [Homo sapiens]
"RG7686 is a first in class monoclonal humanized anti-glypican 3 antibody being developed as single agent and in combination againstmetastatic hepatocellular carcinoma. Its therapeutic activity in pre-clinical models was shown to take place via antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP)." – Roche pipelinegamma1 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-46*01 (82.70%) – (IGHD) – IGHJ5*02) [8.8.8] (1-115) – Homo sapiensIGHG1*01 (CH1 (116-213, hinge (214-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-219')-disulfide withkappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-28*01 (86.00%) -IGKJ2*01) [11.3.9] (1'-112') – Homo sapiens IGKC*01(113'-219')]; dimer (224-224":227-227") – bisdisulfide
>95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
This gene encodes an enzyme with hydroxypyruvate reductase, glyoxylate reductase, and D-glycerate dehydrogenase enzymatic activities. The enzyme has widespread tissue expression and has a role in metabolism. Type II hyperoxaluria is caused by mutations in this gene.
heparan sulfate proteoglycan binding; peptidyl-dipeptidase inhibitor activity; protein binding;